Overview of treatment options for invasive fungal infections | Zendy

Melanie W. Pound | Zendy; Mary L. Townsend | Zendy; V. Paul DiMondi | Zendy; Dustin Wilson | Zendy; Richard H. Drew | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Overview of treatment options for invasive fungal infections

Author(s) -

Melanie W. Pound,

Mary L. Townsend,

V. Paul DiMondi,

Dustin Wilson,

Richard H. Drew

Publication year - 2011

Publication title -

medical mycology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.004

H-Index - 86

eISSN - 1460-2709

pISSN - 1369-3786

DOI - 10.3109/13693786.2011.560197

Subject(s) - posaconazole , voriconazole , amphotericin b , echinocandins , nephrotoxicity , medicine , aspergillosis , amphotericin b deoxycholate , intensive care medicine , candida infections , antifungal , toxicity , immunology , caspofungin , dermatology

The introduction of several new antifungals has significantly expanded both prophylaxis and treatment options for invasive fungal infections (IFIs). Relative to amphotericin B deoxycholate, lipid-based formulations of amphotericin B have significantly reduced the incidence of nephrotoxicity, but at a significant increase in drug acquisition cost. Newer, broad-spectrum triazoles (notably voriconazole and posaconazole) have added significantly to both the prevention and treatment of IFIs, most notably Aspergillus spp. (with voriconazole) and the treatment of some emerging fungal pathogens. Finally, a new class of parenteral antifungals, the echinocandins, is employed most frequently against invasive candidal infections. While the role of these newer agents continues to evolve, this review summarizes the activity, safety and clinical applications of agents most commonly employed in the treatment of IFIs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research